Jason P Rhodes sold $7.1M of DYN
director at Dyne Therapeutics, Inc.. 384,549 shares at an average of $18.47, traded Apr 23, 2026, filed Apr 27, 2026.
Score components
- +15RoleDirector
- +25Trade size$7.1M at market
- +5Share of holdings soldSold 22% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.7%, 3m +42.1%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001577014-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -19,261 | $19.19 | $370k | 1,719,356 | Apr 27, 2026 |
| Apr 23, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -38,322 | $19.19 | $735k | 5,221,857 | Apr 27, 2026 |
| Apr 23, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -377 | $19.19 | $7,235 | 11,286 | Apr 27, 2026 |
| Apr 23, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -15,148 | $19.19 | $291k | 1,270,556 | Apr 27, 2026 |
| Apr 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -36,345 | $18.48 | $672k | 1,683,011 | Apr 27, 2026 |
| Apr 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -72,310 | $18.48 | $1.3M | 5,149,547 | Apr 27, 2026 |
| Apr 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -710 | $18.48 | $13k | 10,576 | Apr 27, 2026 |
| Apr 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -28,583 | $18.48 | $528k | 1,241,973 | Apr 27, 2026 |
| Apr 27, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -45,709 | $18.15 | $830k | 1,637,302 | Apr 27, 2026 |
| Apr 27, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -90,943 | $18.15 | $1.7M | 5,058,604 | Apr 27, 2026 |
| Apr 27, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -894 | $18.15 | $16k | 9,682 | Apr 27, 2026 |
| Apr 27, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -35,947 | $18.15 | $652k | 1,206,026 | Apr 27, 2026 |
Related signals
Other insiders at Dyne Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | DYNbuy Dyne Therapeutics, Inc. | Brian S Posner director | $40k 2,500 shares | +10% | |
| 30Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $107k 5,658 shares | -2% | |
| 20Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $116k 5,035 shares | -3% | |
| 15Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $25k 1,085 shares | -1% | |
| 31Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $131k 4,986 shares | -1% | |
| 55Moderate | Dyne Therapeutics, Inc. | Jason P Rhodes director | $65M 2,586,928 shares | -64% | |
| 23Weak | Dyne Therapeutics, Inc. | Erick Lucera Chief Financial Officer | $47k 1,797 shares | -1% | |
| 16Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $41k 1,556 shares | -1% | |
| 10Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $5,939 226 shares | -0% | |
| 20Weak | Dyne Therapeutics, Inc. | Dirk Kersten director | $6.7M 261,460 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.